Long term clinical outcome of sirolimus drug coated balloons in large coronary vessels
Catheterization and Cardiovascular Interventions · 2024-03 · 103 (4) · 532-538
DOI: 10.1002/ccd.30996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 28.02.2024. Verfasst von Alessandro Sciahbasi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac, Interventional Cardiology, Sandro Pertini Hospital, Rome, Italy. Hauptthemen laut MEDLINE: Coronary Artery Disease, Coronary Restenosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Studies evaluating the safety and efficacy of drug coating balloons (DCB) for the treatment of lesions in large coronary vessel are limited.
Aims
Our study aimed to evaluate the performance of a sirolimus DCB in large coronary arteries.
Methods
We analyzed all the procedures included in the EASTBOURNE Registry (NCT03085823) enrolling patients with a clinical indication to percutaneous coronary intervention performed by a sirolimus DCB according to investigator judgment. In the present analysis, a cut‐off of 2.75 mm was used to define large coronary arteries. Primary endpoint of the study was clinically driven target lesion revascularization (TLR) at 24 months whereas secondary endpoint included procedural success, myocardial infarction (MI), cardiac death and total mortality.
Results
Among the 2123 patients and 2440 lesions enrolled in the EASTBOURNE study between 2016 and 2020, 757 patients/810 lesions fulfilled the criteria for the present analysis. Mean reference vessel diameter was 3.2 ± 0.3 mm with mean lesion length of 22 ± 7 mm. Procedural success was high (96%) and at 2‐year follow up the device showed a good efficacy with a TLR rate of 9%. There were 34 deaths (4.5%), 30 MIs (4%) and 8 BARC type 3–5 bleedings (1.1%). In‐stent restenosis (629 lesions) and de novo lesions (181) were associated with 11% and 4% rates of TLR at 2 years, respectively ( p = 0.003).
Conclusions
Clinical performance of a sirolimus DCB in large coronary artery vessels shows promising signals at 2‐year follow up, both in de novo and in‐stent restenosis lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiac, Interventional Cardiology, Sandro Pertini Hospital, Rome, Italy.
- Department of Cardiac, Pantai Hospital Ayer Keroh, Melaka, Malaysia.
- Department of Cardiac, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
- Department of Cardiac, ASP S. Giovanni di Dio, Agrigento, Italy.
- Department of Cardiac, Ospedale di Rho, Rho, Italy.
- Department of Cardiac, Institute Jantung Negara, Kuala Lumpur, Malaysia.
ORCID-Profile: Alessandro Sciahbasi, Raymundo Ocaranza, Francesco Giannini, Antonio Greco, Bernardo Cortese
Zitieren
APA
Sciahbasi, A., Salvi, N., Heang, T. M., Perez, I. S., Geraci, S., Vaccaro, G., Benincasa, S., Nuruddin, A. A., Ocaranza, R., Giannini, F., Greco, A., & Cortese, B. (2024). Long term clinical outcome of sirolimus drug coated balloons in large coronary vessels. Catheterization and Cardiovascular Interventions, 103(4), 532-538. https://doi.org/10.1002/ccd.30996
Vancouver
Sciahbasi A, Salvi N, Heang TM, Perez IS, Geraci S, Vaccaro G, et al. Long term clinical outcome of sirolimus drug coated balloons in large coronary vessels. Catheterization and Cardiovascular Interventions. 2024;103(4):532-538. doi:10.1002/ccd.30996
BibTeX
@article{Sciahbasi2024,
author = {Sciahbasi, Alessandro and Salvi, Nicolò and Heang, Tay M and Perez, Ignacio S and Geraci, Salvatore and Vaccaro, Giovanni and Benincasa, Susanna and Nuruddin, Amin A and Ocaranza, Raymundo and Giannini, Francesco and Greco, Antonio and Cortese, Bernardo},
title = {Long term clinical outcome of sirolimus drug coated balloons in large coronary vessels},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
volume = {103},
number = {4},
pages = {532--538},
doi = {10.1002/ccd.30996}
}
EUVIMED